about
Beta-lactamase inhibitors from laboratory to clinicCarbapenems: past, present, and futurePenicillin-binding proteins and bacterial resistance to beta-lactamsDiscovery and development of new antimicrobial agents.In vitro investigation of BK-218, a new oral and parenteral cephalosporin.Characterization of beta-lactamases.The potential use of mechanism-based enzyme inactivators in medicine.Structure-activity relationships amongst beta-lactamase inhibitors.Methodology for the study of beta-lactamases.A survey of the kinetic parameters of class C beta-lactamases. Cephalosporins and other beta-lactam compounds.Purification of beta-lactamases by affinity chromatography on phenylboronic acid-agarose.Interactions between active-site-serine beta-lactamases and mechanism-based inactivators: a kinetic study and an overview.The beta-lactamase of Streptomyces cacaoi: interaction with cefoxitin and beta-iodopenicillanate.The active-site-serine penicillin-recognizing enzymes as members of the Streptomyces R61 DD-peptidase family.The association behaviour of beta-lactamases. Sedimentation equilibrium studies in ammonium sulphate solutions.A survey of the kinetic parameters of class C beta-lactamases. Penicillins.Kinetic and physical studies of beta-lactamase inhibition by a novel penem, BRL 42715.The active site of the P99 beta-lactamase from Enterobacter cloacae.Inhibition of class C beta-lactamases by (1'R,6R)-6-(1'-hydroxy)benzylpenicillanic acid SS-dioxide.Do inert beta-lactamase inhibitors act as synergizers of beta-lactam antibiotics? Utility of boric and boronic acids.
P2860
Q24617277-39D707F0-91FF-46E1-87C9-AC601D1B4877Q24634999-C3A529FE-C378-4E64-908F-2A91A2436C4CQ28257231-5C2DB335-194C-4874-B69E-283522930EB0Q34371891-384DE649-58D5-4661-B179-EC9CF1893045Q35248808-4736DCB1-DA72-4579-991E-E13D190436BFQ38640000-B32613D1-C228-4145-A624-7EB457D0F4AAQ39568018-6453BA63-8A5D-4086-82BF-25B98D6CD80CQ39706458-C39EE36D-4188-4D4A-B587-0FC1464B05C2Q39742899-A97CB56A-95D6-49F5-B0FA-5101ECA281D4Q41848422-85543622-DB63-42C5-A53E-D8D3BB846A7FQ41940976-92DB5937-8441-481B-8342-3381CC13930CQ41968772-7E49489A-6D77-4858-A5EF-71C53F6D5760Q42201000-F252BDB0-C456-406C-9386-1C78FDE9BA72Q42201688-876482DB-C2FC-4E11-8C5A-ECA5538FAD2FQ42546333-FF779767-93E7-4BD9-9C95-FB08DD40A768Q42818156-260E35FD-77A7-4BD4-BFC0-EA968A5B5564Q42831248-FC941A74-644F-481D-8CF5-22616A362703Q42848209-78DAF7FE-7C5E-4AE6-A77A-D9B610F290DAQ42848891-F0A74F8A-780D-44EC-A3E4-E20E0C781418Q44711154-6070DF85-8553-4852-A775-B4AF4457F430
P2860
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh
1983年學術文章
@zh-hant
name
beta-Lactamase inhibitors.
@en
type
label
beta-Lactamase inhibitors.
@en
prefLabel
beta-Lactamase inhibitors.
@en
P2860
P356
P1476
beta-Lactamase inhibitors.
@en
P2093
Cartwright SJ
P2860
P304
P356
10.1002/MED.2610030402
P577
1983-10-01T00:00:00Z